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Regression of left ventricular hypertrophy after conversion to Cardiovascular disease is the leading cause of death
nocturnal hemodialysis. in patients with end-stage renal disease (ESRD) [1]. In
Background. Left ventricular hypertrophy (LVH) is an in- patients undergoing conventional (4 hours, 3 times perdependent risk factor for mortality in the dialysis population.
week) hemodialysis, left ventricular hypertrophy (LVH)LVH has been attributed to several factors, including hyperten-
has been identified as an independent risk factor forsion, excess extracellular fluid (ECF) volume, anemia and ure-
mia. Nocturnal hemodialysis is a novel renal replacement ther- mortality [2]. Different authors have estimated the prev-
apy that appears to improve blood pressure control. alence of LVH in the general dialysis population at be-
Methods. This observational cohort study assessed the im-
tween 70 and 80% [3]. Although the exact pathophysiol-pact on LVH of conversion from conventional hemodialysis
ogy of LVH in ESRD is unknown, hypertension, poor(CHD) to nocturnal hemodialysis (NHD). In 28 patients (mean
age 44  7 years) receiving NHD for at least two years (mean extracellular fluid (ECF) volume control, anemia, and
duration 3.4  1.2 years), blood pressure (BP), hemoglobin uremia have been implicated in this process [2, 4].
(Hb), ECF volume (single-frequency bioelectrical impedance) Nocturnal hemodialysis (NHD), a novel mode of renaland left ventricular mass index (LVMI) were determined be-
replacement therapy, provides eight to ten hours of he-fore and after conversion. For comparison, 13 control patients
(mean age 52  15 years) who remained on self-care home modialysis during sleep six to seven nights per week.
CHD for one year or more (mean duration 2.8  1.8 years) This mode of dialysis appears to lower blood pressure
were studied also. Serial measurements of BP, Hb and LVMI (BP) in dialysis patients [5, 6], but the reason(s) whywere also obtained in this control group.
blood pressure falls is unclear. Possible mechanisms in-Results. There were no significant differences between the
two cohorts with respect to age, use of antihypertensive medica- clude a decrease in ECF volume, vasodilation and aboli-
tions, Hb, BP or LVMI at baseline. After transfer from CHD tion of nocturnal obstructive sleep apnea [7, 8]. Uremia
to NHD, there were significant reductions in systolic, diastolic control is superior to that achieved with conventionaland pulse pressure (from 145  20 to 122  13 mm Hg, P 
hemodialysis (CHD) [9]. NHD may therefore represent0.001; from 84  15 to 74  12 mm Hg, P  0.02; from 61 
a beneficial alternative mode of renal replacement ther-12 to 49  12 mm Hg, P  0.002, respectively) and LVMI
(from 147  42 to 114  40 g/m2, P  0.004). There was also apy for the ESRD population.
a significant reduction in the number of prescribed antihyper- The purpose of this study was to determine left ventric-
tensive medications (from 1.8 to 0.3, P 0.001) and an increase
ular mass following conversion of ESRD patients fromin Hb in the NHD cohort. Post-dialysis ECF volume did not
CHD to NHD. Patients receiving self-care home hemo-change. LVMI correlated with systolic blood pressure (r 
0.6, P  0.001) during nocturnal hemodialysis. There was no dialysis also were studied for comparison. Our specific
relationship between changes in LVMI and changes in BP or aim was to determine whether any observed reduction in
Hb. In contrast, there were no changes in BP, Hb or LVMI
left ventricular mass related to one or more of lower BP,in the CHD cohort over the same time period.
improvement in anemia or a decrease in ECF volume.Conclusions. Reductions in BP with NHD are accompanied
by regression of LVH.
METHODS
Key words: daily hemodialysis, home hemodialysis, hypertension, ex-
tracellular fluid volume, blood pressure, end-stage renal disease. All patients participating in the Nocturnal Hemodialy-
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ronto General Hospital self-care home dialysis program the two cohorts. Repeated analysis of variance was used
for multiple comparisons of a continuous variable withinfor a minimum of one year from 1993 onward.
Patients received hemodialysis at home for eight to ten a group. Linear correlation was used to investigate po-
tential associations between variables of interest. Allhours every night. Vascular access was achieved through
either a long-term internal jugular catheter or an arterio- statistical tests were two-tailed with a P value less than
0.05 taken to indicate significance. The SPSS–10 softwarevenous fistula. A dialysate flow rate of 100 to 500 mL per
minute and F40, F50 or F80 polysulfone dialyzers (Fre- program (SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses.senius Medical Care, Lexington, MA, USA) were used.
In the self-care home dialysis program, each patient re-
ceived hemodialysis for four hours, three times per week
RESULTS
via similar vascular access. A dialysate flow rate of 500 to
Twenty-eight patients from the NHD cohort and thir-750 mL per minute and F80 polysufone dialyzers were
teen patients from the CHD group met these inclusionused.
criteria for analysis. Their baseline demographics areIn both cohorts, clinical assessment, including weight,
summarized in Table 1. There was no age differenceheight, BP and hemoglobin (Hb) concentration was per-
between NHD and CHD cohorts (44  7 vs. 52  15,formed initially and every three months. Parathyroid
P  0.05). BP was adequately controlled in both groups.hormone (PTH) was measured initially and every six
The interval between the first and last clinic measure-months. Seated BP was measured during clinic visits by
ment was similar (NHD: 3.4  1.2 years vs. CHD: 2.8 physicians or nurses after five minutes of rest. All BP
1.8 years, P 0.05). Body mass index, BP, antihyperten-measurements were obtained with the same calibrated
sive medication use, Hb and LVH values were similarsphygmomanometer. Echocardiographic data were ob-
in the two groups (Table 1).tained annually and interpreted blindly.
Primary outcomes are summarized in Table 1. WithPrescribed cardiovascular medications were docu-
NHD, there was a significant fall in BP but no change inmented. These included diuretics, beta-blockers, angio-
post-dialysis ECF volume. The need for antihypertensivetensin converting enzyme inhibitors, angiotensin recep-
therapy also decreased yet there were significant reduc-tor antagonists, digitalis, calcium channel blockers, and
tions in systolic, diastolic, mean arterial and pulse pres-vasodilators, were documented. The dose of erythropoi-
sure. There was a significant reduction in LVMI (frometin (EPO) prescribed also was documented.
147  42 g/m2 to 114  40 g/m2, respectively, P  0.004)In the NHD cohort, ECF volume was estimated by
after conversion to nocturnal hemodialysis. At baseline,single-frequency bioelectrical impedance analysis [10] at
7 of 28 (25%) patients in the NHD group and 5 ofbaseline (prior to conversion) and annually thereafter.
13 (38%) patients in the CHD group had normal leftElectrodes were placed on the wrist and foot. Limbs
ventricular mass. After conversion to NHD, 20 of 28with AV access were avoided. The RJL systems device
(71%) patients achieved normal left ventricular mass by(model, BIA–101Q; RJL Systems Inc., Clinton TWP,
Framingham criteria. In contrast, only 4 of 13 (31%) inMI, USA) with Fluid and Nutrition Analysis Software
the CHD group patients had normal left ventricular3.2 (RJL Systems Inc.) was used to compute ECF vol-
mass. Regression of LVMI was achieved through signifi-umes. ECF volume was measured at baseline two to three
cant reductions in end-diastolic diameter, septal wallhours after conventional dialysis, and in the morning
thickness and posterior wall thickness. At baseline, FSafter a regular session of nocturnal hemodialysis.
was similar in the two groups and tended to increaseLeft ventricular mass was calculated from two-dimen-
with long-term NHD. Hb also increased in the NHDsional (2D) echocardiographic images according to the
cohort despite a trend toward lower EPO requirements.formula of Devereux and Reichek [11]. The left ventricu-
PTH tended to decrease in the NHD cohort. In contrast,lar mass index (LVMI) was derived by correcting the
there were no changes in LVMI, BP, Hb, EPO require-left ventricular mass for a body surface area of 1 m2.
ments, PTH or prescription of antihypertensive therapyLeft ventricular hypertrophy was defined as LVMI131
in the CHD group.g/m2 in males and 100 g/m2 in females, as per the Fram-
The impact of NHD on LVH regression was detectedingham Study [12]. Fractional shortening (FS), an index
by one year and was sustained thereafter (Table 2). Post-of left ventricular systolic function, also was assessed.
dialysis ECF volume was unchanged after conversion toThe primary outcome measures were changes in
NHD. There were no significant correlations betweenLVMI, BP, ECF volume and Hb between baseline and
changes in LVMI and changes in systolic BP, pulse pres-the last recorded value for each cohort. Descriptive anal-
sure, Hb or post-dialysis ECF volume. In the NHD pa-yses are presented as mean  standard deviation. The
tients, there was a significant relationship between thepaired Student t test was used for comparison of continu-
final LVMI and the final systolic blood pressure (r ous variables within each cohort. The Student t test was
used for comparison of continuous variables between 0.6, P  0.001; Fig. 1).
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Table 1. Primary outcome variables in chronic (CHD) and nocturnal (NHD) hemodialysis
CHD (N13) NHD (N28)
Variables Initial Final Initial Final
LVMI g/m2 14233 15056b 14742 11440a
SBP mm Hg 13625 13120 14620 12213a
DBP mm Hg 8213 8015 8415 7412a
PP mm Hg 5422 5117 6112 4912a
MAP mm Hg 10015 9714 10416 9011a
BMI kg/m2 25.04.0 25.14.1 24.95.1 25.44.9
ECFV L 17.14.0 16.93.8
PTH pmol/L 40.736.2 40.130.0 34.955.0 16.624.3
HB g/dL 11.714 11.91.1 10.71.3 11.81.6a
EPO IU/week 55003471 81115043 103728065 80906832
Anti-BP meds 1.5 1.5 1.8 0.3a
ACEI: 27% ACEI: 33% ACEI: 19% ACEI: 11%
BB: 27% BB: 27% BB: 23% BB: 78%
CCB: 27% CCB: 27% CCB: 26% ARB: 11%
Vaso: 13% Vaso: 7% Vaso: 14%
Diuretic: 6% Alpha: 7% NTG: 8%
EDD mm 51.44.6 50.69.1 50.77.8 48.47.0a
ESD mm 35.06.9 33.98.6 32.39.7 30.58.1
FS % 345 328 3711 4115
SWT mm 10.91.2 11.41.3 10.92.4 9.62.2a
PWT mm 10.41.6 11.11.5 10.82.1 9.42.4a
Values are presented as mean  standard deviation. Abbreviations are: ACEI, angiotensin-converting enzyme inhibitor; Alpha, alpha receptor blocker; Anti-BP
meds, antihypertensive medications; ARB, angiotensin receptor blocker; BB, beta receptor blocker; CCB, calcium channel blocker; DBP, diastolic blood pressure;
ECFV, extracellular fluid volume; EDD, end-diastolic diameter; ESD, end-systolic diameter; FS, fractional shortening; Hb, serum hemoglobin concentrations; LVMI,
left ventricular mass index; MAP, mean arterial blood pressure; NTG, nitrates; PP, pulse pressure; PTH, parathyroid hormone; PWT, posterior wall thickness; SBP,
systolic blood pressure; SWT, septal wall thickness.
a P  0.05 compared to within-group initial value
b P  0.05 compared to between group final value
Table 2. Changes of principal variables in relation to ment of LVH [14], and in a population of 72 pre-dialysis
time of nocturnal hemodialysis
patients with chronic renal failure, one year of antihyper-
LVMI g/m2 HB g/dL ECFV L tensive therapy with angiotensin converting enzyme in-
Baseline 14742 10.71.3 17.14.0 hibitors reduced the prevalence of cardiac hypertrophy
Year 1 13033a 11.11.2 16.23.3 by 20% [15]. Superior BP control also is thought to
Year 2 10632a 11.71.6 16.23.4
be the principal factor contributing to the regressionYear 3 10219a 11.81.9 15.83.0
of cardiac hypertrophy in patients receiving short dailyValues are presented as mean standard deviation. Abbreviations are: ECFV,
extracellular fluid volume; Hb, serum hemoglobin concentration; LVMI, left dialysis [16–18]. Our findings are consistent with this
ventricular mass index. conclusion. By contrast, CHD, in the present study hada P  0.05 vs. baseline
no impact on either BP or LVMI.
The absence of significant correlation between changes
in LVMI, and changes in either BP, Hb or post-dialysis
DISCUSSION ECF volume following conversion to NHD indicates that
the pathogenesis of LVH in dialysis patients is likelyDialysis patients with LVH have higher mortality rates
multifactorial, and does not depend on the change ofthan those with normal ventricular mass [13]. In the
any unique variable. Changes in ventricular architecturepresent study, we observed regression of LVH after pa-
in this ESRD population, and reverse remodeling follow-tients on CHD were converted to NHD. In contrast, LV
ing long-term NHD, may provide additional insight intomass did not change in those patients who remained on
the relative roles of blood pressure and ECF volumeCHD. Conversion to nocturnal dialysis also resulted in
expansion mediating these changes. Studies of hyperten-a clinically important reduction in blood pressure and
sive patients with primary hypertension implicate bloodin the prescription of antihypertensive therapy.
pressure load in the development of concentric LVHThe absence of any significant change in post-dialysis
(increased wall thickness with increased LV mass), and inECF volume, and the strong correlation between the lower
addition, increased plasma volume in those with eccen-SBP and LVMI after prolonged NHD, point to a signifi-
tric LVH (normal wall thickness with increased LVcant role for hypertension in the pathogenesis of LVH in
mass) [19, 20]. As with previous reports in the ESRDthis population. Indeed, in 432 dialysis patients followed
population [21], our patients at baseline had primarilyserially, a mean arterial blood pressure of greater than
106 mm Hg was strongly associated with the develop- eccentric LVH. Following the conversion to NHD, there
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Fig. 1. Correlation between post-nocturnal
hemodialysis (NHD) systolic blood pressure
(SBP) and current left ventricular mass index
(LVMI) (r  0.6; P  0.001).
were significant reductions in both LV wall thickness and fluid status in mediating these BP changes. Luik et al
challenged ten hemodialysis patients with 3 liters of fluidchamber volume, suggesting a role for reductions in both
and found no relationship between increases in intravas-BP and intravascular volume in this process of regression
cular volume and BP [25]. Even the Tassin group haveand reverse remodeling. However, ECF volume, as esti-
suggested that normotension can be achieved if the dial-mated by bioelectrical impedance analysis (BIA), was
ysis time is long enough to ensure removal of possiblenot diminished by the change in dialysis mode. We pos-
vasoconstrictor factors [26].tulate that the magnitude of daily oscillations in ECF
McGregor et al conducted a randomized crossoverand average ECF volume in patients receiving CHD is
study to establish if long intermittent dialysis was associ-decreased by NHD. A reduction in this diurnal repetitive
ated with better BP control than conventional HD [27].mechanical stimulus to hypertrophy, over time, could
These authors demonstrated a BP lowering effect of longexplain why eccentric hypertrophy was also less promi-
intermittent HD in the absence of any change in dialysisnent following NHD. It is interesting to note that Leenen
ECFV. Nesrallah et al studied ESRD patients who wereand colleagues reached a similar conclusion when de-
randomly assigned to short daily HD or NHD and foundscribing the regression of LVH in 18 hypertensive ESRD
that BP fell in both groups of patients (abstract; Nes-patients after they were placed on chronic ambulatory
rallah et al, J Am Soc Nephrol 12:273A, 2001]. However,peritoneal dialysis (CAPD) [22]. Taken together, these
post-dialysis ECF volume remained unchanged in theobservations suggest that more continuous modes of re-
nocturnal dialysis cohort, in contrast to the short dailynal replacement therapy may promote regression of
dialysis cohort in whom there was a fall in post-dialysisLVH likely through augmenting both volume and pres-
ECF volume. Parfrey et al have reported significant
sure management. LVMI regression upon resolution of uremia by renal
By what mechanism or mechanisms might conversion transplantation in 32 transplant recipients [28]. Thus, the
to NHD lower BP? The hypotensive effect of hemodialy- present study adds to the growing evidence that blood
sis has been attributed to a reduction in ECF volume pressure control in dialysis patients is not only related
[16]. In the Tassin experience, Charzot et al reported to fluid status, but may also arise from superior elimina-
that normotension can be achieved by aggressive control tion of vasoactive and trophic substances such as cate-
of post-dialysis ECF volume [23]. However, our present cholamines or elements of the renin-angiotensin-aldoste-
findings, which indicate that volume control is not neces- rone system.
sary for hypotension to occur, are not unique. Savage et Normalization of Hb levels, as noted in the present
al studied 27 chronic hemodialysis patients with 48 hours analysis, has been studied previously and found not to
of ambulatory BP monitoring between two midweek di- increase BP or affect LV mass [29]. Therefore, the sig-
alysis sessions [24]. They concluded that interdialytic BP nificant changes observed after the switch to NHD are
changes were not related to interdialytic fluid gain, and more likely to arise from the change in dialysis mode
than to the increase in Hb.emphasized the importance of additional factors beyond
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